NO331271B1 - Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling - Google Patents

Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling

Info

Publication number
NO331271B1
NO331271B1 NO20033673A NO20033673A NO331271B1 NO 331271 B1 NO331271 B1 NO 331271B1 NO 20033673 A NO20033673 A NO 20033673A NO 20033673 A NO20033673 A NO 20033673A NO 331271 B1 NO331271 B1 NO 331271B1
Authority
NO
Norway
Prior art keywords
protein
interest
supernatant
secretion
plasmid
Prior art date
Application number
NO20033673A
Other languages
English (en)
Other versions
NO20033673D0 (no
NO20033673L (no
Inventor
Paul Habermann
Johann Ertl
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20033673D0 publication Critical patent/NO20033673D0/no
Publication of NO20033673L publication Critical patent/NO20033673L/no
Publication of NO331271B1 publication Critical patent/NO331271B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033673A 2001-02-20 2003-08-19 Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling NO331271B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108212A DE10108212A1 (de) 2001-02-20 2001-02-20 Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en) 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (3)

Publication Number Publication Date
NO20033673D0 NO20033673D0 (no) 2003-08-19
NO20033673L NO20033673L (no) 2003-10-17
NO331271B1 true NO331271B1 (no) 2011-11-14

Family

ID=7674913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033673A NO331271B1 (no) 2001-02-20 2003-08-19 Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling

Country Status (19)

Country Link
EP (1) EP1364029B1 (no)
JP (1) JP4243104B2 (no)
KR (1) KR100858009B1 (no)
CN (1) CN100500853C (no)
AT (1) ATE314480T1 (no)
AU (1) AU2002231784B2 (no)
BR (1) BRPI0207394B8 (no)
CA (1) CA2438886C (no)
DE (2) DE10108212A1 (no)
DK (1) DK1364029T3 (no)
ES (1) ES2254658T3 (no)
HK (1) HK1065335A1 (no)
IL (1) IL157414A0 (no)
MX (1) MXPA03007114A (no)
NO (1) NO331271B1 (no)
NZ (1) NZ527643A (no)
PE (1) PE20020876A1 (no)
WO (1) WO2002068660A1 (no)
ZA (1) ZA200305869B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP2314602A1 (en) 2003-11-21 2011-04-27 Pfenex, Inc. Improved expression systems with SEC-system secretion
AU2005206951B2 (en) 2004-01-16 2010-08-19 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
AU2008210538B2 (en) 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および/または質が改善されている特定の株を同定する方法
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2010038145A2 (en) * 2008-10-02 2010-04-08 Unitargeting Research As Kit for the optimisation of protein synthesis/secretion
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
ES2853935T3 (es) 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
AU2014362307A1 (en) 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341417C (fr) * 1984-03-27 2003-01-21 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
CA2255396A1 (en) * 1990-11-08 1992-05-09 Nippon Mining Company Limited Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing said vector and manufacturing method ofproducts which is produced from said microorganism
CA2128689A1 (en) * 1992-09-28 1995-04-06 Harold T. Pehr Kicker latch for container closures
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP

Also Published As

Publication number Publication date
MXPA03007114A (es) 2003-11-18
ATE314480T1 (de) 2006-01-15
DE60208343T2 (de) 2006-06-22
BR0207394A (pt) 2004-02-10
DE10108212A1 (de) 2002-08-22
NO20033673D0 (no) 2003-08-19
NO20033673L (no) 2003-10-17
BRPI0207394B8 (pt) 2021-05-25
KR20030074842A (ko) 2003-09-19
JP2004518444A (ja) 2004-06-24
CN1529757A (zh) 2004-09-15
JP4243104B2 (ja) 2009-03-25
CN100500853C (zh) 2009-06-17
ES2254658T3 (es) 2006-06-16
CA2438886A1 (en) 2002-09-06
AU2002231784B2 (en) 2006-10-26
KR100858009B1 (ko) 2008-09-11
WO2002068660A1 (en) 2002-09-06
IL157414A0 (en) 2004-03-28
BRPI0207394B1 (pt) 2015-06-16
DE60208343D1 (de) 2006-02-02
HK1065335A1 (en) 2005-02-18
EP1364029B1 (en) 2005-12-28
CA2438886C (en) 2013-07-23
DK1364029T3 (da) 2006-05-08
PE20020876A1 (es) 2002-11-05
EP1364029A1 (en) 2003-11-26
NZ527643A (en) 2005-07-29
ZA200305869B (en) 2004-06-25

Similar Documents

Publication Publication Date Title
NO331271B1 (no) Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
EP1470236A4 (en) PROCESSES AND COMPOSITIONS FOR PROTEIN EXPRESSION AND CLEANING
WO2005003313A8 (en) Methods and compositions for enhanced protein expression and purification
MX2007006946A (es) Aislado de proteina de soya y proceso para su manufactura.
SG162834A1 (en) Refolding of recombinant proteins
DE60333201D1 (de) Verfahren zur herstellung von proteinen
AU2002360331A1 (en) Egviii endoglucanase and nucleic acids encoding the same
DK0956338T3 (da) Værtsceller og fremgangsmåder til produktion af proteiner
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
ATE370159T1 (de) Streptavidin-bindungspeptid
WO2004053137A3 (en) Method for protein production
MEP27908A (en) Signal sequences for the production of leu-hirudine via secretion by e. coli in a culture medium
AU2003252111A1 (en) Fluorescent proteins, nucleic acids encoding them and methods for making and using them
AU2003251797A1 (en) Methods and compositions for the production, identification and purification of fusion proteins
EP1481061A4 (en) AGAINST DENATURING AGENTS STABLE AND / OR PROTEASERESISTENT, CHAPERONAL OLIGOMER PROTEINS, THESE CODING POLYNUCLEOTIDES AND THEIR USES
AU2003298523A1 (en) Methods for efficient production of mammalian recombinant proteins
DK0941241T3 (da) Bordetella-stamme, som udtrykker hybridet FHA
DK1597369T3 (da) Anvendelse af caspaseenzymer til modning af manipulerede rekombinante polypeptidfusioner
WO2003004599A3 (en) Methods of making and using expression constructs for the expression of recombinant proteins
DK1002056T3 (da) ppGpp-syntease og ekspressionssystem til forbedret fremstilling af protein af interesse
ATE319837T1 (de) Verfahren zur herstellung von rekombinantem trypsin
ATE495245T1 (de) Verbesserte proteinexpression in bacillus subtilis
AU2003287108A1 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
AU2002348573A1 (en) Method of increasing expression of heterologous proteins in plants

Legal Events

Date Code Title Description
MK1K Patent expired